Related Experiment Video

Updated: May 8, 2026

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
08:02

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Published on: March 6, 2012

17.0K

Whole brain radiotherapy in patients with NSCLC and brain metastases

Cécile Le Pechoux1, Frederic Dhermain1, Benjamin Besse2

  • 1Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94800, France.

Lancet (London, England)
|September 9, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

8.2K

Related Experiment Videos

Last Updated: May 8, 2026

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
08:02

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Published on: March 6, 2012

17.0K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

8.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

The oncologist·2026

Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.

JAMA oncology·2026

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol.

PloS one·2026

NSCLC in Vulnerable and Special Populations: Toward Personalized Care.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study.

Lancet (London, England)·2026

Immunogenicity of fractional one-fifth and one-half doses of 17DD yellow fever vaccine compared with full dose in children aged 9-23 months in Uganda: a phase 4, single-blind, randomised clinical trial.

Lancet (London, England)·2026

Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Lancet (London, England)·2026

Gut Microbiota Dysbiosis Mediates 125I-Induced Radiation Colitis via Host Transcriptional Regulation.

Immunity, inflammation and disease·2026

The Spatiotemporal Evolution of Radiation Resistance in Glioblastoma.

Neuro-oncology·2026

Radiotherapy for the Treatment of Peyronie Disease (Induratio Penis Plastica): An American Radium Society (ARS) Appropriate Use Criteria (AUC).

American journal of clinical oncology·2026

Early adverse events and patient-reported outcomes after salvage radiotherapy following prostatectomy according to fractionation schedule: Interim analysis of the phase III URONCOR 06-24 trial.

Clinical and translational radiation oncology·2026

Patterns, causes, and clinical impact of treatment interruption on early outcomes in patients receiving radiotherapy for lung cancer: a retrospective study.

Frontiers in oncology·2026

Feasibility of dose accumulation for assessing treatment-related side effects in MR-guided abdominal SABR: A single-institution study.

Clinical and translational radiation oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us